Enovis (NYSE:ENOV) Upgraded at Wells Fargo & Company

Wells Fargo & Company upgraded shares of Enovis (NYSE:ENOV) to a strong-buy rating in a research report released on Wednesday,Zacks.com reports.

Other equities analysts have also issued research reports about the company. Evercore reaffirmed an “outperform” rating on shares of Enovis in a report on Monday, January 12th. BTIG Research boosted their target price on Enovis from $41.00 to $43.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Zacks Research raised Enovis from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 4th. Needham & Company LLC raised their price target on Enovis from $49.00 to $52.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Finally, Wall Street Zen raised Enovis from a “hold” rating to a “buy” rating in a research report on Saturday, March 14th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $47.43.

Enovis Stock Down 3.7%

Shares of NYSE:ENOV opened at $21.74 on Wednesday. The firm has a 50 day simple moving average of $23.26 and a 200-day simple moving average of $27.54. Enovis has a twelve month low of $21.00 and a twelve month high of $40.69. The company has a current ratio of 2.02, a quick ratio of 1.04 and a debt-to-equity ratio of 0.85. The company has a market capitalization of $1.24 billion, a PE ratio of -1.05 and a beta of 1.46.

Enovis (NYSE:ENOV) last posted its earnings results on Thursday, February 26th. The company reported $0.95 EPS for the quarter, beating analysts’ consensus estimates of $0.81 by $0.14. Enovis had a negative net margin of 52.69% and a positive return on equity of 8.74%. The firm had revenue of $575.76 million for the quarter, compared to the consensus estimate of $584.30 million. During the same period last year, the firm posted $0.98 EPS. The company’s revenue was up 2.6% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities analysts predict that Enovis will post 2.79 EPS for the current fiscal year.

Insider Activity

In other news, insider Oliver Engert purchased 1,000 shares of the business’s stock in a transaction that occurred on Friday, February 27th. The stock was purchased at an average cost of $25.50 per share, with a total value of $25,500.00. Following the completion of the acquisition, the insider directly owned 43,640 shares of the company’s stock, valued at approximately $1,112,820. This trade represents a 2.35% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders have bought 5,000 shares of company stock worth $121,983 in the last quarter. Insiders own 2.70% of the company’s stock.

Institutional Investors Weigh In On Enovis

Institutional investors have recently added to or reduced their stakes in the business. McIlrath & Eck LLC raised its stake in shares of Enovis by 6.9% during the 3rd quarter. McIlrath & Eck LLC now owns 5,517 shares of the company’s stock worth $167,000 after buying an additional 357 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in shares of Enovis by 42.8% in the third quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock valued at $37,000 after buying an additional 367 shares in the last quarter. Amalgamated Bank grew its holdings in Enovis by 3.6% during the third quarter. Amalgamated Bank now owns 16,793 shares of the company’s stock worth $509,000 after acquiring an additional 585 shares during the period. Heritage Family Offices LLP grew its holdings in Enovis by 8.9% during the third quarter. Heritage Family Offices LLP now owns 7,598 shares of the company’s stock worth $231,000 after acquiring an additional 620 shares during the period. Finally, California State Teachers Retirement System raised its position in Enovis by 1.2% in the second quarter. California State Teachers Retirement System now owns 51,713 shares of the company’s stock worth $1,622,000 after acquiring an additional 621 shares in the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.